Community-acquired pneumonia in the elderly
Conditions
Interventions
Feireqing Granules treatment group:Oral administration of Feireqing Granules
Placebo group of Feireqing Granules:Oral placebo of Feireqing Granules
Traditional Chinese Medicine (TCM) treatment based on syndrome differentiation group:For qi deficiency and phlegm-dampness syndrome, prescribe a lung-nourishing and spleen-strengthening formula to res
for qi deficiency and yin deficiency with phlegm-heat syndrome, prescribe a qi-boosting and yin-nourishing formula to clear the lungs
Placebo group treated with traditional Chinese medicine based on syndrome differentiation:Provide corresponding placebo treatment
Sponsors
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
60 Years to 100 Years
Inclusion criteria
Inclusion criteria: Research content 1: 1) Diagnosed with CAP non-severe cases. 2) Diagnosed with phlegm-heat obstructing the lung syndrome according to traditional Chinese medicine differentiation. 3) Aged =60 years. 4) Volunteered to participate in this study and signed the informed consent form. Research content two: 1) Meet the CAP severe diagnosis criteria and have been discharged within 1 week. 2) Be diagnosed with qi deficiency and phlegm-dampness syndrome or qi-yin deficiency and phlegm-heat syndrome according to traditional Chinese medicine (TCM) differentiation. 3) Be aged =60 years. 4) Volunteer to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Concurrent active tuberculosis and pulmonary embolism. 2) Combined with severe cardiovascular and cerebrovascular diseases (malignant arrhythmia, acute myocardial infarction, etc.). 3) Patients with severe liver diseases (such as cirrhosis, portal hypertension, and bleeding caused by esophagogastric varices) and severe kidney diseases (requiring dialysis, kidney transplantation, etc.). 4) Concurrent malignant tumor or immune deficiency disease. 5) Combined with neuromuscular diseases that pose a risk of aspiration. 6) Patients with delirium, various mental illnesses, and other conditions that prevent normal communication. 7) Those who are currently participating in other clinical trials within one month prior to enrollment. 8) Those who are allergic to the therapeutic drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical stabilization time;3-month pneumonia readmission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| length of hospital stay;Incidence of severe pneumonia;3-month pneumonia readmission rate, 3-month all-cause readmission rate;Assessment of quality of life;safety indicators;3-month all-cause readmission rate;3-month all-cause mortality;Pneumonia Patient Satisfaction with Treatment Questionnaire;quality of life;Mini-nutrient assessment scale; | — |
Countries
china
Contacts
Public Contactyanjun
The Third Affiliated Hospital of Beijing University of Chinese Medicine
Outcome results
None listed